Show simple item record

dc.contributor.authorCampbell, Cara L.
dc.contributor.authorJiang, Zhong
dc.contributor.authorSavarese, Diane M. F.
dc.contributor.authorSavarese, Todd M.
dc.date2022-08-11T08:10:05.000
dc.date.accessioned2022-08-23T16:54:36Z
dc.date.available2022-08-23T16:54:36Z
dc.date.issued2001-01-06
dc.date.submitted2007-12-10
dc.identifier.citationAm J Pathol. 2001 Jan;158(1):25-32.
dc.identifier.issn0002-9440 (Print)
dc.identifier.doi10.1016/S0002-9440(10)63940-5
dc.identifier.pmid11141475
dc.identifier.urihttp://hdl.handle.net/20.500.14038/42540
dc.description.abstractPrevious investigations have shown that interleukin-6, a member of the JAK-STAT activating family of cytokines, plays an important role in prostate carcinoma. Here we demonstrate the co-expression of another member of this cytokine family, interleukin-11 (IL-11), and components of its receptor (interleukin-11 receptor; IL-11R), ie, IL-11Ralpha (involved in ligand recognition), and gp130 (involved in signal transduction) in cultured normal and malignant prostate-derived epithelial cell lines. In the DU-145 prostate carcinoma cell line, rhIL-11 stimulates a transient and dose-dependent increase in the tyrosine 705-phosphorylated, active form of STAT3 (STAT3 P-Tyr705), involved in the downstream signaling of IL-11R and other members of the gp130-dependent receptors. The ability of IL-11 to activate STAT3 in prostate-derived cells may be mechanistically important, given recent data suggesting that constitutively activated STAT3 may be associated with the malignant phenotype. In 51 human primary tissues derived from normal prostate, benign prostatic hyperplasia, and prostate carcinomas, IL-11Ralpha and gp130 were commonly expressed, with a statistically significant elevation in the expression of IL-11Ralpha in prostate carcinoma. Also, the tyrosine-phosphorylated, activated form of STAT3 was observed more prominently in the nuclei of cells residing in malignant glands compared to those in nonmalignant samples. Thus, the IL-11 receptor system is up-regulated in prostate carcinoma, and may be one part of a cytokine network that maintains STAT3 in its activated form in these tissues.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11141475&dopt=Abstract ">Link to article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC1850253/?tool=pubmed
dc.subjectAdenocarcinoma
dc.subjectBlotting, Western
dc.subjectCell Line
dc.subjectDNA-Binding Proteins
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectHumans
dc.subjectHyperplasia
dc.subjectImmunohistochemistry
dc.subjectInterleukin-11
dc.subjectInterleukin-11 Receptor alpha Subunit
dc.subjectMale
dc.subjectPhosphorylation
dc.subjectProstate
dc.subjectProstatic Neoplasms
dc.subjectRNA, Messenger
dc.subjectReceptors, Interleukin
dc.subjectReceptors, Interleukin-11
dc.subjectSTAT3 Transcription Factor
dc.subjectTrans-Activators
dc.subjectTumor Cells, Cultured
dc.subjectTyrosine
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleIncreased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma
dc.typeJournal Article
dc.source.journaltitleThe American journal of pathology
dc.source.volume158
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/88
dc.identifier.contextkey403147
html.description.abstract<p>Previous investigations have shown that interleukin-6, a member of the JAK-STAT activating family of cytokines, plays an important role in prostate carcinoma. Here we demonstrate the co-expression of another member of this cytokine family, interleukin-11 (IL-11), and components of its receptor (interleukin-11 receptor; IL-11R), ie, IL-11Ralpha (involved in ligand recognition), and gp130 (involved in signal transduction) in cultured normal and malignant prostate-derived epithelial cell lines. In the DU-145 prostate carcinoma cell line, rhIL-11 stimulates a transient and dose-dependent increase in the tyrosine 705-phosphorylated, active form of STAT3 (STAT3 P-Tyr705), involved in the downstream signaling of IL-11R and other members of the gp130-dependent receptors. The ability of IL-11 to activate STAT3 in prostate-derived cells may be mechanistically important, given recent data suggesting that constitutively activated STAT3 may be associated with the malignant phenotype. In 51 human primary tissues derived from normal prostate, benign prostatic hyperplasia, and prostate carcinomas, IL-11Ralpha and gp130 were commonly expressed, with a statistically significant elevation in the expression of IL-11Ralpha in prostate carcinoma. Also, the tyrosine-phosphorylated, activated form of STAT3 was observed more prominently in the nuclei of cells residing in malignant glands compared to those in nonmalignant samples. Thus, the IL-11 receptor system is up-regulated in prostate carcinoma, and may be one part of a cytokine network that maintains STAT3 in its activated form in these tissues.</p>
dc.identifier.submissionpathoapubs/88
dc.contributor.departmentDivision of Hematology/ Oncology
dc.contributor.departmentDepartment of Pathology
dc.contributor.departmentCytokine/Cytokine Receptor Laboratory
dc.source.pages25-32


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record